AxoGen Appoints New CEO and Board Chair for Strategic Renewal
Company Announcements

AxoGen Appoints New CEO and Board Chair for Strategic Renewal

AxoGen (AXGN) has issued an announcement.

The Company has energized its leadership team with the appointment of Mr. Dale as the new CEO and Mr. Thomas stepping in as the Chair of the Board, aiming to steer the organization towards new horizons. This strategic move, detailed in a recent press release, is expected to bring fresh perspectives and drive to the Company’s vision and operational dynamics, while not affecting the company’s legal standings or filings.

See more data about AXGN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAxoGen Seeks Accelerated FDA Review for Avance Nerve Graft®
TheFlyAxoGen completes submission of BLA to U.S. FDA for Avance Nerve Graft
GlobeNewswireAxogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App